

## SIOPE – ENCCA Scientific Papers

### Posters:

G. Vassal, M. Schrappe, et al., [The SIOPE Strategic Plan: A European Cancer Plan for Children and Adolescents](#), SIOPE, Brussels, Belgium (presented at European Cancer Congress 2015 and SIOPE Congress 2015)

R. Ladenstein, M. Schrappe, K. Pritchard-Jones, Gilles Vassal, et al, *ENCCA – European Activities and Achievements with Potential Interest Outside of Europe*, SIOPE Congress 2015

R. Ladenstein, M. Schrappe, K. Pritchard-Jones, Gilles Vassal, et al, *Major Achievements of the European Network for Cancer Research in Children and Adolescents*, SIOPE Congress 2014

V Segura , A Alspach A, A Di Cataldo A, et al., [Non High-Risk Neuroblastoma European Strategy: SIOPE LINES Protocol Implementation, Challenges, and Achievements](#), Congress 'Advances in neuroblastoma research', Koln, Germany, May 2014

Segura V, Schleiermacher G, Ambros P, Di Cataldo A, Bermúdez J et al., [LINES as a paradigm of risk-adapted therapies using prognostic biomarkers: a SIOPE trial](#), Congress 'European CanCer Congress' 2013, Amsterdam, The Netherlands, September 2013

Segura V, Alspach A, Di Cataldo A, et al., [LINES: European low and intermediate risk neuroblastoma \(a SIOPE study\)](#), International symposium 'Paediatric Cancer Research at the INTERFACE', Vienna, Austria, June 2013

F. Rifatbegovic, A. Weinhäusel, et al., [Does the handling of blood and bone marrow affect the gene expression of disseminated neuroblastoma cells?](#), Children's Cancer Research Institute, Tumor Biology Group, Vienna, Austria

I.M. Ambros, C. Brunner et al., [Genomic background of neuroblastomas with intra-tumor heterogeneity of MYCN amplification](#), Children's Cancer Research Institute, Tumor Biology Group, Vienna, Austria.

### ENCCA Abstracts presented at SIOPE Congress 2014 (Toronto, CA):

Name	Type of pres.	Title
<b>Project Coordinator</b> Ruth Ladenstein	Poster presentation	<i>'Major achievements of the European Network for Cancer research in Children and Adolescents (ENCCA)'</i>
<b>WP9</b> Martin Schrappe	Poster presentation	<i>'Improved therapeutic strategies using predictive biomarkers in</i>

**WP10**

Adela Cañete Nieto

Poster presentation

*paediatric ALL: An activity within the EU network ENCCA to introduce newly discovered molecular information into clinical practice'*

['How the European Clinical Trial Directive impacts trial implementation: LINES, on behalf of SIOPEL cooperative Group'](#)

*'Development of a novel web-based consultation service for a paediatric rare tumor: The SIOPEL Clinician Online Consultation Service'*

**WP12**

Arun Atreiya Rangaswami, Piotr Czauderna

Oral presentation

*'The Survivorship Passport for long-term care of childhood cancer survivors. An initiative of the European Network for research on Cancer in Children and Adolescents (ENCCA)'*

**WP13**

Riccardo Haupt, Chiara Dellacasa, Sabine Karner, Leontien Kremer, Christophe Bergeron, Silvia Caruso, Davide Saraceno, Roderick Skinner, Vera Morsellino, Lars Hjorth

e-poster

1. *'Are we looking in the right place? A study of time to diagnosis of cancer in children and young adults within Yorkshire secondary care services'*, C Lethaby, SE Kinsey, SV Picton, M van Laar, R Phillips, RG Feltbower.

2. *'Missing data and survival analysis of central nervous system tumours amongst children and adolescents in Yorkshire, UK, 1990-2009'*, M van Laar, DC Greenwood, DP Stark, RG Feltbower.

**WP17**

Richard Feltbower

Poster presentation

1. Oral presentation in the ICCCP program: *'Nothing about you without you!: Parents' and Patients' views on clinical trials and bio-banks. Results from the EU-FP7 ENCCA project, and lessons for the future'*

2. Poster: *'Working together on*

**WP18**

Jean-Claude Dupont

Poster and oral presentation

*ethics: Ethical deliberations involving professionals as well as patients' and parents' representatives. Lessons and Results from the EU-FP7 ENCCA project'*

## Scientific Articles:

### 2016

**6 March 2016:** K. Pritchard-Jones et al., [Evidence for a delay in diagnosis of Wilms' tumour in the UK compared with Germany: implications for primary care for children](#), Arch Dis Child  
doi:10.1136/archdischild-2015-309212

**18 January 2016:** H. Kovar et al., [The second European interdisciplinary Ewing sarcoma research summit – A joint effort to deconstructing the multiple layers of a complex disease](#), Oncotarget, Advance Publications 2016, pp. 1-12

**January 2016:** P. Czauderna et al., [The Children's Hepatic tumors International Collaboration \(CHIC\): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model](#), Volume 52, Pages 92–101

### 2015

**21 December 2015:** J. Carretier, et al. [A Review of Health Behaviors in Childhood and Adolescent Cancer Survivors: Toward Prevention of Second Primary Cancer](#), Journal of Adolescent and Young Adult Oncology (JAYAO)

**15 December 2015:** Piotr Czauderna et al., [The Children's Hepatic tumors International Collaboration \(CHIC\): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model](#), EJC, January 2016, Volume 52, Pages 92–101

**10 December 2015:** Rebora P, Galimberti S, Valsecchi MG, [Using multiple timescale models for the evaluation of a time-dependent treatment](#), Stat Med. 34(28), pp 3648-60

**26 November 2015:** D. Hayn, *Piloting the European Patient Identity Management (EUPID) concept to facilitate Secondary Use of Neuroblastoma Data from Clinical Trials and Biobanking*, Abstracts of the 4th Neuroblastoma Research Symposium

**November 2015:** Koumakis, L.; Potamias, G.; Marias, K.; Tsiknakis, M., [An algorithmic approach for the effect of transcription factor binding sites over functional gene regulatory networks](#), in *Bioinformatics and Bioengineering (BIBE), 2015 IEEE 15th International Conference on*, vol., no., pp.1-6, 2-4 Nov. 2015, doi: 10.1109/BIBE.2015.7367662

**26 October 2015:** DP Bernasconi, P Rebora, S Iacobelli, MG Valsecchi, L Antolini, [Survival Probabilities with Time Dependent Treatment Indicator: Quantities and Non-Parametric Estimators](#), *Statistics in Medicine*, 1097-0258

**1 October 2015:** M. S. Isakoff, S. S. Bielack, P. Meltzer, R. Gorlick, [Osteosarcoma: Current Treatment and a Collaborative Pathway to Success](#), *Journal of Clinical Oncology*, 33 (28)

**26 September 2015,** G. Vassal et al., [The SIOPE Strategic Plan, A European Cancer Plan for Children and Adolescents](#)

**11 September 2015:** F. Rifatbegovic, M. R. Abbasi, S. Taschner-Mandl, M. Kauer, A. Weinhäusel, R. Handgretinger, P. F. Ambros, [Enriched Bone Marrow Derived Disseminated Neuroblastoma Cells Can Be a Reliable Source for Gene Expression Studies—A Validation Study](#), *Plos One*, doi:10.1371/journal.pone.0137995

**July 2015:** L. Hjorth et al., [Survivorship after childhood cancer: PanCare: A European Network to promote optimal long-term care](#), *EJC*, Volume 51, Issue 10, Pages 1203–1211

**18 June 2015:** [Architecture for an Advanced Biomedical Collaboration Domain for the European Paediatric Cancer Research Community \(ABCD-4-E\)](#), Michael Nitzlnader, Markus Falgenhauer, Christian Gossy, Günter Schreier, *Studies in Health Technology and Informatics*, Volume 212: eHealth2015 – Health Informatics Meets eHealth

**18 June 2015:** [Standardized Data Sharing in a Paediatric Oncology Research Network – A Proof-of-Concept Study](#), Nina Hochedlinger, Michael Nitzlnader, Markus Falgenhauer, Stefan Welte, Dieter Hayn, Lefteris Koumakis, George Potamias, Manolis Tsiknakis, Davide Saraceno, Eugenia Rinaldi, Ruth Ladenstein, Günter Schreier, *Studies in Health Technology and Informatics* Volume 212: eHealth2015 – Health Informatics Meets eHealth, 27-34

**June 2015:** E. Steliarova-Foucher et al., [Registration of childhood cancer: Moving towards pan-European coverage?](#), *EJC*, Volume 51, Issue 9, Pages 1064-1079

**6 April 2015:** N. Hochedlinger, *Standardisierter Datenaustausch in medizinischen Forschungsnetzwerken mit Anwendung in der pädiatrischen Onkologie*, Master Thesis, Graz University of Technology

**April 2015:** M Izzo, G Arnulfo, MC Piastra, V Tedone, L Varesio, MM Fato, [XTENS – A JSON-based Digital Repository for Biomedical Data Management](#), *Bioinformatics and Biomedical engineering*, Volume 9044, pp 123-130

**21 March 2015:** Rota, M., Antolini, L., & Valsecchi, M.G., [Optimal cut-point definition in biomarkers: the case of censored failure time outcome](#), *BMC Med Res Methodol.* 15(1), pp 24-34

**31 December 2014:** A. D. Jakes, P Marec-Berard, R. S. Phillips, D. P. Stark, <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4270154/><http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4270154/>, J Adolesc Young Adult Oncol. 2014 Dec 1;3(4):144-152,

**27 November 2014:** G. Vassal et al., [Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer](#), *European Journal of Cancer*, doi: <http://dx.doi.org/10.1016/j.ejca.2014.10.029>

**October 2014:** M. R. Abbasi, R. Ladenstein, I. M. Ambros, P. F. Ambros, [Bone marrows from neuroblastoma patients: An excellent source for tumor genome analyses](#), *Molecular Oncology*, doi:[10.1016/j.molonc.2014.10.010](https://doi.org/10.1016/j.molonc.2014.10.010)

**September 2014:**

- Adamson P. C., et al., [Drug discovery in paediatric oncology: roadblocks to progress](#), *Nature Reviews Clinical Oncology* Vol. 11/Issue 12 Nature Publishing Group United Kingdom 16/09/2014, pp. 732-73, doi:[10.1038/nrclinonc.2014.14](https://doi.org/10.1038/nrclinonc.2014.14)
- Maschietto M, Charlton J et al., [The IGF signalling pathway in Wilms tumours - A report from the ENCCA Renal Tumours Biology-driven drug development workshop](#), *Oncotarget* Oncotarget, Vol. 5, No. 18 Impact Journals, 16/09/2014, pp. 8014 - 8026
- Charlton J ,et al., [Methylome analysis identifies a Wilms tumor epigenetic biomarker detectable in blood](#), *Genome Biology* Vol. 15/Issue 8, doi:[10.1186/s13059-014-0434-y](https://doi.org/10.1186/s13059-014-0434-y)

**12 August 2014:** I. M. Ambros, C. Brunner, R. Abbasi, C. Frech and P. F. Ambros, [Ultra-high density SNParray in neuroblastoma molecular diagnostics](#), *Front Oncol.* 2014; 4: 202. doi: [10.3389/fonc.2014.00202](https://doi.org/10.3389/fonc.2014.00202)

**July 2014:**

- 30 July 2014, Milani G, Rebora P, Accordi B, et al., [Low PKC \$\alpha\$  expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome](#), *Oncotarget.* 2014 Jul 30;5(14):5234-45
- S. Bielack, *Multimodale Therapie des Osteosarkoms Gesicherte Erkenntnisse und offene Fragen*, JATROS I Seite 136 Hämatologie & Onkologie 3/14
- K. S. Bull, C. R. Kennedy et al., [Improved health-related quality of life outcomes associated with SHH subgroup medulloblastoma in SIOP-UKCCSG PNET3 trial survivors](#), *Acta Neuropathol*, Volume 128, Issue 1, pp 151-153, DOI [10.1007/s00401-014-1300-4](https://doi.org/10.1007/s00401-014-1300-4)

**24 June 2014:** M. Wilhelm, D. Stark et al., [ENCCA WP17-WP7 consensus paper on teenagers and young adults \(TYA\) with bone sarcomas](#), *Annals of Oncology*, 00: 1–, 2014, doi:[10.1093/annonc/mdu153](https://doi.org/10.1093/annonc/mdu153)

**June 2014:** M. Nitzlnader, G. Schreier, [Patient Identity Management for Secondary Use of Biomedical Research Data in a Distributed Computing Environment](#), *eHealth2014 – Health Informatics Meets eHealth*, doi:[10.3233/978-1-61499-397-1-211](https://doi.org/10.3233/978-1-61499-397-1-211)

**19 May 2014:** P. Rebora , M. G. Valsecchi, [Survival estimation in two-phase cohort studies with application to biomarkers evaluation](#), Statistical Methods in Medical Research, Doi: 10.1177/0962280214534411

**6 May 2014:** M Izzo, F Mortola, G Arnulfo, MM Fato, L Varesio, [A digital repository with an extensible data model for biobanking and genomic analysis management](#), BMC Genomics, 2014, 15 (Suppl 3):S3, pp 1-15

**1 May 2014:** J. K. Anninga et al., [Workshop report on the 2nd Joint ENCCA/EuroSARC European bone sarcoma network meeting: integration of clinical trials with tumour biology](#), Clinical Sarcoma Research 2014, 4:4

**6 April 2014:** D Cangelosi, M Muselli, S Parodi, F Blengio, P Becherini, R Versteeg, M Conte, Luigi Varesio, [Use of Attribute Driven Incremental Discretization and Logic Learning Machine to build a prognostic classifier for neuroblastoma patients](#), BMC Bioinformatics, 2015, 15 (suppl 5):S4, pp 1-15

**3 March 2014:** Nitzlander M., *Konzept eines IHE-basierten Medizinischen Forschungsnetzwerkes in der Cloud*, Master Thesis, UMIT Private University of Health Sciences, Medical Informatics and Technology

**7 February 2014:** S Pillozzi, B Accordi, P Rebora et al., *Differential expression of hERG1A and hERG1B genes in pediatric acute lymphoblastic leukemia identifies different prognostic subgroups*, Leukemia (2014) 28, 1352–1355, Doi: 10.1038/leu.2014.26

**1 February 2014:** C. Kennedy et al. on behalf of the PNET4 study group of the SIOPE Brain Tumour Group, [Quality of Survival and Growth in Children and Young Adults in the PNET4 European Controlled Trial of Hyperfractionated Versus Conventional Radiation Therapy for Standard-Risk Medulloblastoma](#), International Journal of Radiation Oncology, Volume 88, Issue 2, Pages 292–300

**February 2014:** P. Czauderna et al., [Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy](#), Curr Opin Pediatr., 2014 Feb;26(1):19-28. doi: 10.1097/MOP.0000000000000046

**February 2014:** R. L. Meyers et al., [Hepatoblastoma state of the art: pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation](#), Current Opinion in Pediatrics Vol. 26/Issue 1 Lippincott Williams and Wilkins doi: 10.1097/MOP.0000000000000042

**January 2014:** P. Czauderna et al., [The treatment of hepatoblastoma: Its evolution and the current status as per the SIOPEL trials](#), Journal of Indian Association of Pediatric Surgeons Vol. 19/Issue 4 Medknow Publications and Media Pvt. Ltd Indi, doi: 10.4103/0971-9261.142001

**January 2014:** E. Steliarova Foucher, L. Frazier, *Childhood Cancer*, in World Cancer Report 2014 (an IARC monograph), pp. 69-76

**23 December 2013:** A. van der Veer, M. Zaliova et al., [IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL](#), Blood 2013 Oct 10;122(15):2622-9

**2 December 2013:** J. Kowalczyk, [Towards reducing inequalities: European Standards of Care for Children with Cancer](#), European Journal of Cancer, Volume 50, Issue 3 , Pages 481-485

**December 2013:** Di Giulio P, Arnfield A, English MW, Fitzgerald E, Kelly D, Jankovic M, and Gibson F. ['Collaboration between doctors and nurses in children's cancer care: insights from a European project'](#), European Journal Oncology Nursing 17(6):745-9

**14 November 2013:** C. Kennedy, K. Bull, M. Chevignard et al., [Quality of Survival and Growth in Children and Young Adults in the PNET4 European Controlled Trial of Hyperfractionated Versus Conventional Radiation Therapy for Standard-Risk Medulloblastoma](#), on behalf of the, PNET4 study group of SIOPE Brain Tumour Group, Int J Radiation Oncol Biol Phys, Vol. 88, No. 2, pp. 292-300, <http://dx.doi.org/10.1016/j.ijrobp.2013.09.046>

**31 October 2013:** A. Laprie, A. K. LaMarre, D. A. Haas-Kogan, 1 February 2014, [Hyperfractionation: Fractious or Not?](#), Editorial, Int J Radiation Oncol Biol Phys, Vol. 88, No. 2, pp. 269-271, <http://dx.doi.org/10.1016/j.ijrobp.2013.10.044>

**18 October 2013:** M Zaliova et al., [ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia](#), Leukemia (2014) 28, 182–185; doi:10.1038/leu.2013.282

**6 September 2013:** D. L.-Terrada, R. Alaggio, M. T. de Dávila, P. Czauderna et al., [Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium, Modern Pathology \(2013\), 1–20](#)

**12 September 2013:** R. Franca, P. Rebora, E. Athanasakis et al., [TNF- \$\alpha\$  SNP rs1800629 and risk of relapse in childhood acute lymphoblastic leukemia: relation to immunophenotype](#), Future Medicine Ltd, Vol. 15/Issue 5, pp. 619-627, Doi: 10.2217/pgs.13.249

**16 July 2013:** M. Rota, L. Antolini, [Finding the optimal cut-point for Gaussian and Gamma distributed biomarkers](#), Computational Statistics and Data Analysis 69 (2014) 1–14

**28 May 2013:** S. Chiaretti, A. Vitale, G. Cazzaniga et al., [Clinico-biologic features of 5202 acute lymphoblastic leukemia patients enrolled in the Italian AIEOP and GIMEMA Protocols and stratified in age-cohorts](#), Haematologica, 2013 doi 10.3324/haematol.2012.080432

**12 April 2013:** C. Palmi, M.G. Valsecchi, G. Longinotti et al., [What is the relevance of Ikaros gene deletions as prognostic 1 marker in pediatric 2 Philadelphia negative B-cell precursor acute lymphoblastic leukemia?](#), Haematologica, doi: 10.3324/haematol.2012.075432

**April 2013:** S. Bielack, B. Kempf-Bielack, T. Von Kalle et al., [Controversies in childhood osteosarcoma](#), Minerva Pediatr 65(2):125-148, 2013)

**20 February 2013:** R. Sullivan, J. R. Kowalczyk et al., *New policies to address the global burden of childhood cancers*, *The Lancet Oncology*, pp. 125-135, doi: 10.1016/S1470-2045(13)70007-X

**20 February 2013:** K. Pritchard-Jones et al., *Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries*, *The Lancet Oncology*, doi:10.1016/S1470-2045(13)70010-X

**20 February 2013:** G. Vassal et al., *New drugs for children and adolescents with cancer: the need for novel development pathways*, *The Lancet Oncology*, doi:10.1016/S1470-2045(13)70013-5

**20 February 2013:** I. Magrath, E. Steliarova-Foucher, et al., *Paediatric cancer in low-income and middle-income countries*, *The Lancet Oncology*, doi: 10.1016/S1470-2045(13)70008-1

**11 February 2013:** S. Galimberti, M. G. Valsecchi, [Multivariate permutation test to compare survival curves for matched data](#), *BMC Medical Research Methodology*, 13:16, doi:10.1186/1471-2288-13-16

**28 January 2013:** L. Bastian, J. Hof, M. Pfau et al., [Synergistic antileukemic activity of bortezomib and HDACis in preclinical models of B cell precursor – ALL via modulation of the p53, p53, PI3K/AKT and NF-κB](#), *Clinical Cancer Research*, 2012 doi:10.1158/1078-0432.CCR-12-1511

**21 January 2013:** M. Ezzalfani et al.: *Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities*, *Stat Med.* 2013 Jan 21. doi: 10.1002/sim.5737

**January 2013:** R Bellazzi, A Dagliati, F Licciulli, P Romano, L Varesio, M Cannataro, [Concepts in IT solutions for integrating clinical and molecular data to support biomedical research: from biobanks to knowledge repositories](#), *ACM SIGBioinformatics Record*, Volume 3 Issue 1, pp 18-21

## 2012

**1 December 2012:** P. Czauderna, R. Meyers, E. Hiyama et al.: *Children's hepatoma international collaboration (CHIC): novel initiative creating a global retrospective clinical database and an international risk stratification system: experience of the ENCCA consortium*, *Pediatr. Blood Cancer* 2012; vol. 59, nr 6, s. 987

**1 December 2012:** D. Lopez-Terrada, S. Ranganathan, R. Allagio et al., *Development and validation of a revisited international classification of hepatoblastoma (HBL), hepatocellular carcinoma (HCC) and transitional liver tumours (TLT) in children: a proposal from the International Paediatric Liver Pathology Expert Committee from COG, GPOH, JPLT and SIOPEL Groups, after Los Angeles Symposium and Paris Workshop in 2011*, *Pediatr. Blood Cancer* 2012; vol. 59, nr 6, s. 986

**December 2012:** Franca R. et al., *Glutathione S-transferase homozygous deletions and relapse in childhood acute lymphoblastic leukemia: a novel study design in a large Italian AIEOP cohort*, *Pharmacogenomics*. 2012 Dec;13(16):1905-16. doi: 10.2217/pgs.12.169



**30 September 2012:** Rebora P., Galimberti S., *Sample size calculation for recurrent events data in one-arm studies*, Pharm Stat. 2012 Nov-Dec;11(6):494-502. doi: 10.1002/pst.1541. Epub 2012 Sep 30

**July 2012:** Billingham L, [Small sample sizes in clinical trials: a statistician's perspective](#), Clinical Investigation (2012) 2(7), 655-57, doi: 10.4155/cli.12.62

**13 June 2012:** S. Krentz et al., *Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia*, Leukemia 2012. doi: 10.1038/leu.2012.155

**June 2012:** Bagnasco F. et al., *Risk of repeated febrile episodes during chemotherapy-induced granulocytopenia in children with cancer: a prospective single center study*, J Chemother. 2012 Jun;24(3):155-60. doi: 10.1179/1973947812Y.0000000002

**29 May 2012:** [H. Kovar et al., The First European Interdisciplinary Ewing Sarcoma Research Summit](#), Frontiers in Paediatric Oncology, 2012

**8 May 2012:** Deley MC et al., *Taking the long view: how to design a series of Phase III trials to maximize cumulative therapeutic benefit*, Clin Trials. 2012 Jun;9(3):283-92. doi: 10.1177/1740774512443430

**May 2012:** L. Koumakis et al., [Coupling Regulatory Networks and Microarrays: Revealing Molecular Regulations of Breast Cancer Treatment Responses](#), Lecture Notes in Computer Science 7297: 239-246 (2012)

**February 2012:** C. Seerainer et al., [HL7 CDA R2 Based Document Sharing in Biomedical Research: Design of a Severe Adverse Event \(SAE\) Report Document](#), European Journal for Biomedical Informatics

## 2011

**December 2011:** L. Antolini, M.G. Valsecchi, [Performance of binary markers for censored failure time outcome: nonparametric approach based on proportions](#), Stat Med, December 2011

**September 2011:** [D. M. Thomas, M. Wilhelm, A.-M. Cleton-Jansen, S. Bielack: Workshop Report on the European Bone Sarcoma Networking Meeting: Integration of Clinical Trials with Tumor Biology](#), Journal of Adolescent and Young Adult Oncology, September 2011

**10 August 2011:** J. Hof et al.: [Mutations and Deletions of the TP53 Gene Predict Nonresponse to Treatment and Poor Outcome in First Relapse of Childhood Acute Lymphoblastic Leukemia](#), J Clin Oncol/ 29/, 3185-3193, doi: 10.1200/JCO.2011.34.8144